For the 42 individuals BC dataset (23 TP53 and 19 PIK3CA), 80% (27 individuals) was used for training, while the remaining 20% was split into 6 individuals for validation and 9 individuals for testing, ensuring consistent evaluation. This evidence concerns the gene TP53 and breast cancer.